New York State Common Retirement Fund Purchases 16,341 Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

New York State Common Retirement Fund raised its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 8.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 205,495 shares of the company's stock after purchasing an additional 16,341 shares during the quarter. New York State Common Retirement Fund owned 0.37% of PROCEPT BioRobotics worth $11,972,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Thematics Asset Management acquired a new stake in shares of PROCEPT BioRobotics in the fourth quarter worth approximately $46,000. Signaturefd LLC increased its holdings in shares of PROCEPT BioRobotics by 26.7% during the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after acquiring an additional 145 shares during the last quarter. Nisa Investment Advisors LLC raised its position in PROCEPT BioRobotics by 32.5% in the first quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company's stock valued at $64,000 after purchasing an additional 270 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in PROCEPT BioRobotics in the fourth quarter valued at approximately $207,000. Finally, Freestone Grove Partners LP bought a new stake in PROCEPT BioRobotics during the fourth quarter worth $207,000. 89.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $61.49, for a total value of $1,537,250.00. Following the completion of the sale, the director owned 14,363 shares of the company's stock, valued at $883,180.87. This trade represents a 63.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders sold 100,000 shares of company stock worth $6,271,250. Corporate insiders own 17.40% of the company's stock.

PROCEPT BioRobotics Stock Down 2.2%

NASDAQ:PRCT traded down $1.30 during midday trading on Monday, reaching $57.05. 1,127,984 shares of the stock traded hands, compared to its average volume of 857,668. The stock has a market capitalization of $3.16 billion, a PE ratio of -33.56 and a beta of 1.07. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.75 and a current ratio of 8.95. The business has a 50-day moving average of $58.73 and a two-hundred day moving average of $61.79. PROCEPT BioRobotics Corporation has a 12-month low of $47.04 and a 12-month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.04. The firm had revenue of $69.16 million for the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative net margin of 36.20% and a negative return on equity of 28.09%. The company's revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.51) earnings per share. On average, equities analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PRCT has been the topic of several recent analyst reports. Morgan Stanley reduced their price target on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating on the stock in a report on Tuesday, July 15th. Truist Financial lowered their price target on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. Oppenheimer began coverage on shares of PROCEPT BioRobotics in a research report on Monday, July 7th. They set a "market perform" rating on the stock. Stephens assumed coverage on PROCEPT BioRobotics in a report on Wednesday, July 9th. They issued an "overweight" rating and a $70.00 price target for the company. Finally, Bank of America dropped their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $84.13.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).